On August 19, 2020 Prescient Therapeutics (ASX: PTX) reported Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s novel approach to treating cancer using targeted and cellular therapy (Press release, Prescient Therapeutics, AUG 19, 2020, View Source;utm_medium=rss&utm_campaign=prescient-therapeutics-is-developing-novel-personalised-therapies-against-a-range-of-cancers-small-caps [SID1234565490]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prescient Therapeutics is the only ASX-listed company developing CAR-T technology, which is a type of cellular therapy that reprograms a cancer patient’s immune cells to recognise and destroy cancer.

The clinical stage oncology company recently announced it will be teaming up with the Peter MacCallum Cancer Centre to advance its cell therapy research, including next generation CAR-T.